Algert Global’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-72,532
| Closed | -$2.71M | – | 1341 |
|
|
2026
Q2 | $2.71M | Sell |
72,532
-25,270
| -26% | -$939K | 0.03% | 765 |
|
|
2026
Q1 | $3.55M | Buy |
+97,802
| New | +$4.37M | 0.05% | 545 |
|
|
2025
Q2 | – | Sell |
-26,287
| Closed | -$882K | – | 1201 |
|
|
2025
Q1 | $882K | Sell |
26,287
-2,490
| -9% | -$93K | 0.02% | 797 |
|
|
2024
Q4 | $1.47M | Sell |
28,777
-14,000
| -33% | -$783K | 0.03% | 705 |
|
|
2024
Q3 | $2.19M | Buy |
42,777
+1,070
| +3% | +$55.2K | 0.06% | 524 |
|
|
2024
Q2 | $1.87M | Buy |
41,707
+6,667
| +19% | +$308K | 0.06% | 489 |
|
|
2024
Q1 | $1.64M | Buy |
35,040
+17,360
| +98% | +$679K | 0.06% | 474 |
|
|
2023
Q4 | $629K | Buy |
+17,680
| New | +$542K | 0.03% | 749 |
|
|
2023
Q2 | – | Sell |
-18,710
| Closed | -$300K | – | 1113 |
|
|
2023
Q1 | $300K | Buy |
18,710
+1,304
| +7% | +$24.1K | 0.01% | 947 |
|
|
2022
Q4 | $319K | Hold |
17,406
| – | – | 0.02% | 922 |
|
|
2022
Q3 | $342K | Sell |
17,406
-2,673
| -13% | -$54.5K | 0.02% | 915 |
|
|
2022
Q2 | $374K | Sell |
20,079
-4,880
| -20% | -$97.4K | 0.03% | 857 |
|
|
2022
Q1 | $548K | Buy |
+24,959
| New | +$505K | 0.04% | 773 |
|
Other funds holding CRNX
Algert Global's CRNX Position: Q3 2026 in Review
Algert Global sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2026, closing a stake of 72,532 shares — an estimated $2.71M sold.
Algert Global first reported a position in CRNX in Q1 2022 and held it in 13 quarters. The position peaked at $3.55M in Q1 2026. 2 funds tracked by Wall St. Rank hold CRNX as of Q3 2026.
- Algert Global reported no remaining Crinetics Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- Algert Global sold 72,532 Crinetics Pharmaceuticals shares in Q3 2026, an estimated $2.71M.
- Algert Global first reported a position in Crinetics Pharmaceuticals in Q1 2022 and held it in 13 quarters.
- Algert Global's Crinetics Pharmaceuticals position peaked at $3.55M in Q1 2026.
- 2 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2026.
Based on Algert Global's 13F filing for Q3 2026, filed 17 Nov 2026.